RxSight Q2 revenue $34.9M, +68% YoY; raises FY2024 guidance above prior range

RxSight, Inc.

2024-Q2 EPS reported -$0.40 revenue$64,399,000

Revenue $34.9M in Q2 2024, up 68% from $20.8M in Q2 2023; LAL volume +92% to 24,214 lenses.
Net loss improved to $(6.1)M ($(0.16)/share) from $(13.8)M ($(0.40)/share) in Q2 2023; adjusted net income $0.0M.
Installed LDD base reached 810 units (+55% YoY); 78 LDDs sold in Q2 (+16% YoY).
FY2024 revenue guidance raised to $139-140M (56-57% growth) from prior $132-137M; gross margin guidance unchanged 68-70%.
Cash $233.3M at June 30, 2024, includes $107.5M net proceeds from public offering closed May 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.